http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006008674-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03d0f52bb4069f8a19d70dcfb697c67a |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate | 2005-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c52012906b1777b49e1c96ea168ad769 |
| publicationDate | 2006-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2006008674-A |
| titleOfInvention | Anti-allergic drug and drug application |
| abstract | PROBLEM TO BE SOLVED: To provide a drug for suppressing allergic symptoms occurring in eyes or nose. When an allergic reaction occurs inside the eyelid of a mammal, the drug A2 containing the compound A1 that suppresses the allergic reaction or its precursor A0 is brought into contact with the outer surface of the eyelid. Or when an allergic reaction occurs inside the nose, by contacting the outer surface of the nose with a drug A2 containing the compound A1 that suppresses the allergic reaction or its precursor A0, the A1 or A0 is brought into contact with the surface A drug containing A1 or A0 that percutaneously penetrates into the cells and suppresses the internal allergic reaction to 0 to 95% when there is no contact. [Selection figure] None |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7128370-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012143487-A |
| priorityDate | 2004-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 160.